Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market capAny size
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Monday, October 19, 2026· 10818 stock ideas· 219 writers·
19,087 views· 8,812 clicks

From X

@aleabitoreddit

Serenity on X

$LITE CEO interview on demand, counterparty + financing risk: - "CFO of $GOOGL came on and reported capex going up Y/Y, we expect hyperscalers for report an increase in capex in earnings. Based on what we see, we see their spend going up." - "The purchase agreements we have, to a large degree, are noncancellable." - The difference between Lumentum and companies like $AVGO, "we are not as dependent on AI datacenter buildout going forward" There's a conversion between electrical products to optical products" creating structural demand. Q: When do you see able to see yourself having more inventory? (catching up to surge in demand) - When we look at demand, there is "no end in sight" TLDR: Financing risk and demand aren't equally distributed across AI supply chains. But markets are just selling everything off together. As for photonics in specific, I said this before, but increasing optical content per XPU + CPO/NPO adoption keeps going up so we'll likely see sector spend go up, even if aggregate capex goes down. There's the usual "no end to demand in sight" commentary, but $LITE does have capacity commitments into 2029 now... and are negotiating for 2030. (with new information that most of which are likely hyperscalers + non-cancellable) So doesn't quite sound like it's all over for the AI trade, especially photonics.
@calvinblissett 1 click

Calvin Blissett on X

$CCLD questions I have so far for Stephen Synder (CEO) interview if I am missing anything please let me know Charlie Munger famously talked about the importance of distinguishing between technological improvements where the economic benefits “stick to our ribs as owners” and those where “all of the advantages from great improvements are going to flow through to the customers.” (Stripe Press) I think it’s fair to say AI will lower costs overall for the RCM industry for those able to take advantage of it. McKinsey estimates that AI enablement of the revenue cycle could reduce cost to collect by 30% to 60%. (McKinsey & Company) We are already beginning to see this play out: roughly 20% to 40% of organizations report broad or enterprise-wide use of AI-enabled tools across different parts of the revenue cycle, while 70% to 90% of decision-makers expect to increase spending on AI-enabled RCM capabilities over the next three years. (Oliver Wyman) How is this playing out currently, and how do you see it progressing? More specifically, where do you think the economic benefits of AI ultimately accrue? Will AI make the strong stronger and the weak weaker—allowing scaled, technologically capable RCM providers to lower their costs faster and potentially furthering industry consolidation? Or, as AI tools become increasingly commoditized and accessible, could they instead level the playing field and erode some of CareCloud’s existing competitive cost advantage? A bit similar to the last question: Could AI change the dynamic of struggling companies not being able to upgrade products and or win clients. Allowing them to improve and compete hence lowering acquisition opportunities? How much growth aside from obviously inorganic acquisitions is existing customers expanding versus new clinics signing up? Do you think about size when acquiring or is it purely a factor of opportunity and fit. It would seem intuitive smaller acquisitions are easier and cheaper. Is there a pace or target you have in mind regarding acquisitions One shareholder asked for more metrics/metrics with news. Just granularity, Shareholder assumes it will be on earnings call but affects of data breach and portion if any that isn’t covered by insurance. What you’re seeing and anticipate seeing in terms of loss of current customers and momentum in future sales. A majority of the employees are in Pakistan which is currently going through a turbulent time and is basically a junta. Do you think there's any need to de-risk it? I believe the ROI from acquisition is at the midpoint of purchase multiple (.6-1x) and target contribution margin (25-30%) on a full year time frame after 9 months to get there to be About 34%. If your stock had the same FCF yield how would you weight buybacks vs acquisitions. Given the same assumed 34% full year after achieving targets on acquisition In Q2 2026, Hadi said: “OurAI and acquisition strategies have become a single, unified growth engine.” Does that mean that AI strategy/product development has similar economics or is it table stakes and has to be invested in merely to keep up?

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps
KRYS · short

Krystal Biotech INC

Krystal Biotech is a profitable commercial-stage biotech with an $8.7 billion enterprise value and one FDA-approved topical gene therapy,…

KRYS $9.4B
Value Investors Club

Ally Financial: The Next Vintage

Ally Financial's Q2 FY26 consumer auto originations rose 21% to $13.3 billion as newer, 9%+ yield vintages replace troubled 2022 loans;…

ALLY $11B
TSOH Investment Research

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Saturday, October 17 31 stock ideas
  • SiriusXM: Dirt Cheap, Looming Catalysts, Short Squeeze Candidate Eagle Point Capital
  • Expert Call | Q3 2026 Optical Components Market Dynamics, Vendor Market Share, & 2027 Growth Outlook P Equity Research
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 108

YouTube 4

Blogs 17

Seeking Alpha 52 of 238

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

89 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick